Clinical Trials Logo

Acne Inversa clinical trials

View clinical trials related to Acne Inversa.

Filter by:
  • None
  • Page 1

NCT ID: NCT04476043 Recruiting - Clinical trials for Hidradenitis Suppurativa

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Start date: August 26, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36 -week open-label extension period.

NCT ID: NCT04214483 Recruiting - Acne Vulgaris Clinical Trials

A Pilot Study to Explore the Role of Gut Flora in Acne

Start date: March 2, 2020
Phase:
Study type: Observational

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

NCT ID: NCT04092452 Recruiting - Acne Inversa Clinical Trials

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Start date: December 2, 2019
Phase: Phase 2
Study type: Interventional

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

NCT ID: NCT04019041 Completed - Clinical trials for Hidradenitis Suppurativa

A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

Start date: September 16, 2019
Phase: Phase 2
Study type: Interventional

This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other week injections of bermekimab or placebo, and 1/3 will receive weekly injections of placebo.

NCT ID: NCT03852472 Active, not recruiting - Clinical trials for Hidradenitis Suppurativa

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

Start date: December 28, 2018
Phase: Phase 2
Study type: Interventional

Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

NCT ID: NCT03275870 Completed - Clinical trials for Hidradenitis Suppurativa

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

Start date: September 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients suffer from recurring painful abscesses and scarring in their armpits, under the breasts, groin and other areas of the body. The cause of the disease is still unknown and common treatments are only sometimes effective. Overactivity of the immune system has been associated with HS and molecules that cause inflammation have been found in the skin from people with HS. Current therapies have long-term risks including antibiotic resistance and the investigators aim to find new safe and effective therapies for HS. Hydroxychloroquine is a medication that has been used safely in other diseases for many years. The investigators believe that hydroxychloroquine has the potential to improve HS through multiple mechanisms. Patients enrolled in this study will be treated with hydroxychloroquine for 6 months. The investigators also aim to look at the blood of patients with HS to look for inflammatory molecules that we could possibly target for the treatment of HS. Blood samples will be taken at baseline and following 6 months of treatment.

NCT ID: NCT03238469 Terminated - Clinical trials for Hidradenitis Suppurativa

Microwave Ablation in Mild Axillary Hidradenitis Suppurativa

WAVE
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

With microwave ablation (MWA), using the heat generated from electromagnetic waves in the microwave energy spectrum, hair follicles and apocrine glands in the (hypo)dermis are ablated through thermolysis. MWA was recently approved for the treatment of axillary hyperhidrosis (miraDry) and removal of axillary hair (miraSmooth). By permanent removal of hairs and sweat glands, the investigators hypothesize a beneficial and long-term sustainable preventive effect of MWA in HS patients.

NCT ID: NCT03203122 Recruiting - Clinical trials for Hidradenitis Suppurativa

Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa

Start date: August 7, 2017
Phase: N/A
Study type: Interventional

6 monthly treatments with IPL laser in patients with Hidradenitis Suppurativa. The effect in measured on several severity scores.

NCT ID: NCT01352078 Recruiting - Wounds Clinical Trials

Wound Etiology and Healing Study

WE-HEAL
Start date: May 2011
Phase:
Study type: Observational

The purpose of the WE-HEAL Study is to help researchers use human tissue samples and health records to study the reasons why some patients heal quickly and some have problems healing wounds. All patients seen with an open wound or hidradenitis suppurativa are invited to participate. Information from this research may help to understand how to prevent and treat certain diseases.